Testing umbilical cord blood transplant for young people with blood cancers
Tests cord blood transplant in children and young adults with leukemia or lymphoma.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Cord Blood Transplantation in Children and Young Adults With Blood Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 71 people, planned
- Started
- 28 Apr 2026
- Expected to end
- 28 Apr 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cord Blood Units
- Total Body Irradiation
- Cyclophosphamide
- Fludarabine
- Clofarabine
- Busulfan
- Thiotepa
- Tacrolimus
- Mycophenolate Mofetil
- Cyclosporine
- Record updated
- 14 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults up to 26 years old with high-risk blood cancer who need a donor stem cell transplant using cord blood.
- Age
- Up to 26 years old.
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia, acute lymphoblastic leukemia, other acute leukemias, myelodysplastic syndrome, non-Hodgkin lymphoma or Hodgkin lymphoma at high risk of relapse. Cohort 1: no earlier donor transplant, in remission. Cohort 2: very high-risk disease, such as relapse after an earlier donor transplant or up to 30% blasts in the bone marrow.
- Earlier treatment
- Cohort 1: no earlier donor transplant, and no related or unrelated donor with a close tissue match available within 4 weeks. Cohort 2: if an earlier donor transplant was done, the new one is at least 4 months later.
- Biomarker or test result
- Bone marrow blasts under 5% in remission for most patients. For acute lymphoblastic leukemia in Cohort 1, no measurable residual disease by flow cytometry. Organ tests such as liver, lung, heart and kidney function must be in the required range.
Main reasons for not taking part
- Active leukemia in the brain or spinal fluid (CNS)
- Active and uncontrolled infection at the time of transplant
- HIV infection or HTLV-1 positive
- Pregnancy or breast feeding
- Cohort 2: a donor transplant in the last 4 months
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- A patient cannot be considered eligible for this study unless ALL of the following conditions are met
- ° Disease type
- Cohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of informed consent with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses:
- Acute myelogenous leukemia (AML):
- Complete first remission (CR1) with blast count < 5% by bone marrow morphology at high risk for relapse such as any of the following:; Known prior diagnosis of myelodysplasia (MDS); High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53); Requirement for 2 or more inductions to achieve CR1; Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and/or gene therapy or cell therapy); Presence of Minimal/Measurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation); Other high-risk features not defined above
- Complete second remission (CR2) or subsequent remission, with blast count < 5% by bone marrow morphology
- Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable
- Acute lymphoblastic leukemia (ALL):
- Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following:; Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality; Failure to achieve complete remission (CR) after four weeks of induction therapy (transplant to follow antibody therapy and/or CAR T cells); Persistence or recurrence of MRD on therapy (Transplant to follow antibody therapy and/or CAR T cells); T-ALL in CR even with presence of MRD; Other high-risk features not defined above
- Complete second remission (CR2) or subsequent remission with MRD negative status by multiparameter flow cytometry; Relapse in less than 36 months from CR1; Relapse for T-ALL
- Patients after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy that resulted in MRD negative status by multiparameter flow cytometry
- Other acute leukemias:
- Leukemias of ambiguous lineage or of other types with < 5% blasts by bone marrow morphology
- Patients with persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in < 5% of cells
- Chronic myelogenous leukemia: Patients with history of blast crisis or accelerated phase
- Any leukemia that developed after gene therapy or cell therapy
- Myelodysplastic Syndrome (MDS):
- Any IPSS risk category with life-threatening cytopenia(s)
- Any IPSS risk category with high risk cytogenetic/molecular findings (5, 7, 8, complex karyotype, or TP53)
- Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high risk of relapse or progression if not in remission:
- Patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell NHL) in CR
- Patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm
- Patients with HL without progression of disease (POD) after salvage chemotherapy with no single lesion ≥5 cm; Cohort 2: Very High-Risk disease:
- Patients in CR (bone marrow blasts <5% by morphology) who had prior allogeneic transplant and disease recurrence. The second transplant will take place at least 4 months after the first; Acute myelogenous leukemia (AML) or Myelodysplastic Syndrome (MDS): Relapse after previous transplant, in CR after induction therapy. MRD positive status by multi-parameter flow cytometry is accepted; Acute lymphoblastic leukemia (ALL): Relapse after previous transplant, in CR after induction therapy and/or antibody therapy/CAR T cells. MRD positive status after targeted therapy, as evaluated by multi-parameter flow cytometry is accepted; Other: patients with leukemia or lymphoma, who, in the opinion of their physician, are not likely to have reduction in disease burden with further chemotherapy
- Patients with relapsed/refractory disease at either first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology. ° Relapse after previous transplant with < 30% blasts by bone marrow morphology, or with cytogenetic, flow cytometric, or molecular abnormalities in < 30% of bone marrow cells, after induction therapy; ° Primary refractory or relapsed AML with < 30% blasts by bone marrow morphology or with cytogenetic, flow cytometric, or molecular abnormalities in < 30% of bone marrow cells; ° Age 0-26 years at the time of informed consent; ° Performance: Karnofsky (≥16 years) or Lansky score (<16 years) of ≥70% (see Appendix A); ° Not Pregnant and Not Nursing; ° Required Organ Function; Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia); ALT ≤ 3 x upper limit of normal; Pulmonary function (FVC, FEV1 and DLCO corrected for hemoglobin) ≥ 50% predicted; In young children unable to perform pulmonary function testing: pulse oximetry >92% in room air, and a normal CT of the chest (if CT is not normal, the child needs to be evaluated and cleared by pediatric pulmonary physician); Left ventricular ejection fraction > 50%; Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7; Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and must be willing to use an effective contraceptive method while enrolled in the study; Renal: Serum creatinine (SCr) ≤ 1.5 x normal for age. If SCr is outside the normal range, then CrCl > 50 mL/min (calculated or estimated) or estimated GFR (mL/min/1.73m2) >30% of predicted normal for age; Normal GFR by Age : Mean GFR +- SD (mL/min/1.73m\^2) 1 week : 40.6 + / - 14.8 2-8 weeks : 65.8 + / - 24.8 >8 weeks : 95.7 + / - 21.7 2-12 years : 133.0 + / - 27.0 13-21 years (males) : 140.0 + / - 30.0 13-21 years (females) : 126.0 + / - 22.0; GFR, glomerular filtration rate; SD, standard deviation; Greater than 2 years old: Normal GFR is 100 mL/ min; Infants: GFR must be corrected for body surface area
Who cannot take part
- Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome; Cohort 2 Very High-Risk Disease (additional to above):; ° Allogeneic HCT in the preceding 4 months; Note (1): Prior checkpoint inhibitors/blockade in the last 12 months: eligibility to be discussed with study PI; Note (2): For patients with known HBV and/or HCV infection :
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Active and uncontrolled infection (bacterial/fungal/viral) at time of transplant
- HIV infection
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- ° Inadequate performance status/ organ function
- ° Active CNS leukemic involvement
- Chloroma >2 cm
- Seropositivity for HTLV-1
- Pregnancy or breast feeding
- Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests
Where in United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Andromachi Scaradavou, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
The 2 groups in the trial
- Cohort 1: Patients with High-Risk DiseaseTreatment being tested
Participants in complete remission (CR; bone marrow blasts \<5% by morphology) with no prior allogeneic transplant, who require allogeneic transplantation and do not have human leukocyte antigen (HLA)-matched related or unrelated donors readily available within 4 weeks. For participants with AML/MDS, MRD (Measurable/Minimal Residual Disease) positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry); participants with ALL need to be in MRD negative status (evaluated by multiparameter flow cytometry).
Treatment: Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine, Busulfan, Thiotepa, Tacrolimus, Mycophenolate Mofetil, and Cyclosporine
- Cohort 2: Patients with Very High-Risk DiseaseTreatment being tested
1. Participants in CR (bone marrow blasts \<5% by morphology) who had prior allogeneic transplant and disease recurrence. 1. Participants with AML/MDS: MRD positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry) 2. Participants with ALL: MRD positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry). 3. The second transplant will take place at least 4 months after the first. 2. Participants with relapsed/refractory disease at first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology.
Treatment: Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine, Busulfan, Thiotepa, Tacrolimus, Mycophenolate Mofetil, and Cyclosporine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies
- Plain-language title
- Testing umbilical cord blood transplant for young people with blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 14 May 2026